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Among the multiple factors concurring to Alzheimer’s disease (AD) pathogenesis, greater
attention should be devoted to the role played by infectious agents. Growing epidemi-
ological and experimental evidence suggests that recurrent herpes simplex virus type-1
(HSV-1) infection is a risk factor for AD although the underlying molecular and functional
mechanisms have not been fully elucidated yet. Here, we review literature suggesting
the involvement of HSV-1 infection in AD also brieﬂy mentioning possible pharmacological
implications of these ﬁndings.
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ALZHEIMER’S DISEASE, APP PROCESSING AND AMYLOID-β
PRODUCTION/ACCUMULATION
Alzheimer’s disease (AD) is a neurodegenerative disorder char-
acterized by progressive decline in cognitive functions leading to
memory loss and dementia. It involves degeneration of limbic
and cortical brain structures, especially in the temporal lobe. In
2010, it was estimated that 35.5 million individuals were affected
by dementia in the world with a prediction that this number will
increase to 65.7 million by 2030, and 115.4 million by 2050. The
World Alzheimer Report 2010 (AD International) estimated that
the total costs of dementia in 2010 were US$ 604 billions. Most
(>90%) AD cases are sporadic. Only a minority of them have a
genetic inheritance and are referred to as familial AD. The main
risk factor for AD is aging. The disease afﬂicts 10% of the pop-
ulation over the age of 65 and 50% of the population over the
age of 85. Several factors may increase the chances to develop AD
(Imtiaz et al., 2014). Among the “genetic” risk factors, the carriage
of a type 4 allele of the apolipoprotein E gene (APOE-ε4) has been
widely recognized (see references in Kim et al., 2009). Among the
“environmental” risk factors, persistent brain infections, particu-
larly those induced by herpes simplex virus type-1 (HSV-1), seem
to play a key role in AD pathogenesis. In a multifactorial dis-
ease like AD, to identify the contribution made by each factor and
the underlying mechanisms is critical to the development of new
therapeutic strategies to prevent the disease and/or slow down its
progression.
From the neuropathological point of view, the brains of
AD sufferers are characterized by the presence of two major
hallmarks mainly located in the hippocampus and cortex: extra-
cellular amyloid plaques composed of insoluble aggregates of
the amyloid-β protein (Aβ) and intraneuronal neuroﬁbrillary
tangles, composed of hyperphosphorylated Tau protein (Kosik
et al., 1986). Numerous other conditions, among which oxidative
stress (Mattson et al., 1993) and inﬂammation, due to microglia
activation and astrocytosis, may concur to produce the structural
and functional alterations typically found in AD brain (Kitazawa
et al., 2004).
Amyloid-β protein is a small protein (generally composed of
40 to 43 amino acids) generated by the proteolytic cleavage of
the amyloid precursor protein (APP), a ubiquitous transmem-
brane protein whose functional role in cell biology has been only
partially discovered. APP seems to be involved in neurite out-
growth and synaptogenesis, neuronal protein trafﬁcking along
the axon, transmembrane signal transduction, cell adhesion and
Ca2+ signaling (Zheng and Koo, 2006; Octave et al., 2013). Among
the various isoforms of APP, due to alternative splicing of APP
gene located on chromosome 21 in humans, those of 695-amino
acid length is prevalent in neurons whereas the other two forms,
APP751 and APP770, are expressed in other tissues (Zhang et al.,
2011).
Amyloid precursor protein is normally subjected to processing
by speciﬁc enzymes called“secretases”(Nunan and Small, 2000). It
may be processed along two different pathways. The ﬁrst one, that
ismost frequent and“non amyloidogenic”, involves sequential pro-
teolytic cleavages by the α- and γ-secretases. The former cuts APP
at a position 83 amino acids from the C-terminus, thus producing
a large N-terminal domain (sAPPα), normally secreted into the
extracellular medium, whose function is not well deﬁned. On the
opposite site, the other 83-amino-acid C-terminal fragment (C83)
is retained in the membrane and it is subsequently cleaved by the
γ-secretase complex (that consists of presenilins, nicastrin, ante-
rior pharynx-defective 1 and presenilin enhancer 2), producing a
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short fragment that is generally considered non-toxic and known
as “p3”. The amyloidogenic pathway begins when APP undergoes
cleavage by the β-secretase, also known as β-site APP cleaving
enzyme 1 or BACE-1 (Vassar et al., 1999). β-secretase cuts APP
16 amino acids before α-secretase and yields two species, the large
N-terminal ectodomain of the precursor and the 99-amino acidC-
terminus stub (C99). Subsequent cleavage of the latter fragment by
γ-secretase results in the formation of Aβ species containing 40 to
42 amino acids. This also means that APP cleavage by α-secretase
prevents the Aβ formation. On the other C-terminal side of APP,
γ-secretase (in both amyloidogenic and non-amyloidogenic path-
ways) also generate the “APP intracellular domain” (AICD), that
has been reported to modulate the transcription of several genes
(including APP itself, BACE-1 and the Aβ-degrading enzyme
neprilysin), to regulate apoptosis and contribute to AD patho-
genesis (Octave et al., 2013). In APP, the amino acid threonine
in position 668 (Thr668) is an important site for its processing.
Indeed, APP phosphorylation at Thr668 resulted in increased Aβ
formation (Lee et al., 2003; Pierrot et al., 2006). This amino acid
is on the C-terminal region of APP and its phosphorylation also
regulates the activity of AICD. In fact, when AICD is phosphory-
lated at Thr668 it interacts with the Fe65 adapter protein (Bórquez
and González-Billault, 2012) and enters the nucleus, where it may
regulate gene transcription and induce neurodegeneration (Chang
et al., 2006).
Amyloidogenic cleavage of APP is not conﬁned to cell mem-
brane; it also takes place in several cellular compartments (Vetrivel
and Thinakaran, 2006), including the intermediate compartment
of the endoplasmic reticulum (Cook et al., 1997), the trans-Golgi
network (Choy et al., 2012), and the endosomal/lysosomal system,
where APP processing is regulated by cytoplasmic phosphoryla-
tion at Thr668 (Lee et al., 2003). For these reasons, Aβ species
may be secreted directly into the extracellular space, where their
subsequent aggregation promotes senile plaque formation. Alter-
natively, it may remain within the cell or may be re-internalized in
neurons, where it accumulates (Mohamed and Posse de Chaves,
2011). Some recent ﬁndings suggest that Aβ accumulating in neu-
rons, particularly in the formof small oligomers (especially dimers
and trimers) is the major determinant of the synaptic damage
that highly correlates with the cognitive deﬁcits characterizing
the early phases of the disease preceding neuronal death (Tam-
pellini et al., 2007; Mucke and Selkoe, 2012; Ripoli et al., 2013).
However, Aβ is not a mere toxic peptide. It is constitutively pro-
duced and secreted by cells and, especially when present at very
low concentration (in the range of pM), it even supports synapses
by increasing synaptic strength in the hippocampus (Puzzo et al.,
2008, 2011).
In addition to secretases, APP may be processed by caspases
(in particular caspase-3), especially in cells undergoing apop-
tosis (Gervais et al., 1999; Pellegrini et al., 1999; Fiorelli et al.,
2013). In neurons, caspase-induced processing of APP generates
a C-terminal fragment (C31) with neurotoxic potential (Lu et al.,
2003; Nguyen et al., 2008). Moreover, Fiorelli et al. (2013) showed
that caspases cleavage generates two APP fragments (APP-Fs) of
25–35 kDa that are recognized by anti-Aβ antibodies.
Among the genetic risk factors for AD, the carriage of APOE-
ε4 allele plays a major role. Apolipoproteins carry lipids in
the circulation and regulate lipid metabolism. ApoE, expressed
predominantly in astrocytes, is suggested to be involved in redis-
tribution of cholesterol and phospholipids during membrane
remodeling (Holtzman et al., 2012). Links betweenAD andAPOE-
ε4 are multiple: ApoE protein exists in 4 isoforms (E1 to E4), with
ApoE3 being the most common allele, and it seems to play a role
in Aβ ﬁbrillogenesis and oligomerization as well as in Aβ clear-
ance. Differently from the other three variants, ApoE4 exhibits
scarce ability to bind Aβ, thus its expression contributes to Aβ
accumulation and aggregation inside neurons and inﬂuences the
formation of the parenchymal amyloid plaques (Holtzman et al.,
2012; Verghese et al., 2013). When human ApoE isoforms were
expressed in APP transgenic mice, differences in extracellular Aβ
accumulation were observed in an isoform-dependent manner
(E2 < E3 < E4; Holtzman et al., 2000). Similar results were also
recently obtained by Hashimoto et al. (2012) who reported that
the levels of Aβ oligomers in APOE ε4/ε4AD brains were 2.7 times
higher than those found in APOE ε3/ε3 AD brains, and that ApoE
increased Aβ oligomer levels in an isoform-dependent manner
(E2< E3< E4).
Finally, alterations of intracellular Ca2+ homeostasis and sig-
naling have also been implicated in AD pathogenesis. It is well
known that intracellular Ca2+, besides playing a pivotal role
in a large number neuronal functions, is a critical determi-
nant of neuronal survival and death (Piacentini et al., 2008a,b;
Maiti et al., 2011; Bading, 2013). Several reports demonstrated
correlation between Ca2+ homeostasis dysregulation leading
to increased intracellular Ca2+ levels and AD (Green, 2009).
Interestingly, ApoE expression in neuronal and glial cells cor-
relates with increased intracellular Ca2+ concentrations in an
isoform-dependent manner (E2< E3< E4; Müller et al., 1998).
HOW CAN HSV-1 BE INVOLVED IN AD?
Herpes simplex type 1 virus is a neurotropic double-stranded
DNA virus that primarily infects epithelial cells of oral and nasal
mucosa. Here virus undergoes lytic replication; the newly pro-
duced viral particles may enter sensory neurons and, by axonal
transport, reach the trigeminal ganglion where usually establishes
a latent infection. The virus undergoes periodic reactivation cycles
in which the newly formed viral particles are transported back to
the site of primary infection through the sensory neurons, caus-
ing the well-known clinical lesions (i.e., cold sores and blisters).
However, the bipolar trigeminal ganglion neurons also project to
the trigeminal nuclei located in the brainstem. From here, neurons
project to the thalamus to ﬁnally reach the sensory cortex. This is
the path through which the reactivated virus may reach the cen-
tral nervous system (CNS), where it may cause acute neurological
disorders like encephalitis [herpes simplex encephalitis (HSE)] or
a mild, clinically asymptomatic, infection, or establish life-long
latent infection (Kastrukoff et al., 1982; Lewandowski et al., 2002;
references in Dobson et al., 2003). The weakening of immune sys-
tem occurring during aging may favor this process. In addition to
the neuronal route, HSV-1 may enter the CNS through the blood
stream, as demonstrated by Burgos et al. (2002, 2003, 2005). Many
experimental evidence, described below, suggest that accumula-
tion of intracellular damage caused by repeated cycles of viral
reactivation may concur to neurodegeneration.
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Some reports suggest that during infection herpes virus inter-
acts with several human proteins that it uses to enter the cell
and to move from plasma membrane to the nucleus and back
(reviewed in Carter, 2008). HSV-1 also uses the host’s tran-
scriptional machinery to replicate and binds to proteins that
control immune surveillance or apoptosis. Noteworthy, in the
attempt to eliminate the virus, host may even cause cell damage
via immune and inﬂammatory responses targeting the virus-
containing cells. If this happens in the CNS, HSV-1-induced
inﬂammatory response may result in HSE or, in milder cases, in
cell death and neurodegeneration.
Several epidemiological, immunological and molecular evi-
dence link HSV-1 infections to AD pathogenesis. HSV-1 is a
ubiquitous virus that affects more than 80% of people over 65
worldwide. The ﬁrst evidence suggesting the involvement of HSV-
1 in AD dates back to 1982 and is based on the observation
that people surviving to HSE showed clinical signs reminiscent
of AD (i.e., memory loss and cognitive impairment), and that
brain regions primarily affected in HSE (limbic system, frontal
and temporal cortices) were the same regions compromised in AD
(Ball, 1982). During the last 30 years several research groups have
conducted many studies providing solid support to the involve-
ment of HSV-1 infection in AD pathogenesis. Here we will brieﬂy
summarize the main results of these researches.
EPIDEMIOLOGICAL DATA
Several studies have been performed to assess the presence of
HSV-1 in the brain of AD patients. After the ﬁrst observa-
tions made by Ball (1982), other studies have demonstrated
that HSE affected the same brain areas involved in AD in
humans as well as in rodent experimental models (Damasio
and Van Hoesen, 1985; Caparros-Lefebvre et al., 1996; Beffert
et al., 1998; Wu et al., 2003; Taylor et al., 2007; Ando et al.,
2008). Jamieson et al. (1992) and Itzhaki et al. (1997) reported
that a high proportion (about 60%) of brains of elderly peo-
ple contained latent HSV-1 DNA, especially in the CNS regions
critically involved in AD. When present in AD brains, HSV-1
DNA was primarily located within amyloid plaques (Wozniak
et al., 2009a). Whether or not the virus contributes to activation
of pro-neurodegenerative pathways may largely depend on sev-
eral host factors, including genetic predisposition, as described in
greater detail below. Many infectious agents whose pathogenetic
role has been established in other CNS diseases (e.g., varicella
zoster virus, causing meningitis or encephalitis; Epstein–Barr
virus, associated to both multiple sclerosis and CNS lymphoma;
human herpes virus 6, associated to seizure in children) may
infect subjects without producing evident clinical signs. On the
other hand, even in the presence of “clinically silent” infec-
tion, virus may periodically reactivate and replicate in the CNS
(Peter and Sevall, 2001; Bearer, 2012). There is no clear evi-
dence on whether HSV-1 reaching the brain and infecting neurons
resides there in latent form. However, the detection of HSV-1
DNA in the cerebro-spinal ﬂuid (Deatly et al., 1988; Peter and
Sevall, 2001; Plentz et al., 2008) suggests that HSV-1 replicates
in the CNS (Bearer, 2012). The presence of HSV-1 proteins
in hippocampal neurons of mice infected intraperitoneally with
HSV-1 was demonstrated by Burgos et al. (2006a) who also
showed that virus is reactivated by hyperthermia. After every
reactivation, the newly produced viral particles generated by
this “silent” replication and potentially reaching the brain might
act, in a drop by drop fashion, to produce local brain dam-
ages that may largely differ from those of acute diseases like
HSE. It has been recently reported that in brain of infected
but asymptomatic mice, HSV-1 reactivation was associated to
neuroinﬂammation and to the appearance of several mark-
ers of neurodegeneration including Tau hyperphosphorylation
(Martin et al., 2013).
IMMUNOLOGICAL DATA
A number of studies have been conducted to demonstrate the
association between AD and HSV-1 infection by searching for
antibodies against HSV-1 in the blood of AD patients. These
studies revealed a strong correlation between AD occurrence
and HSV infection or reactivation, as addressed in a longitudi-
nal study including 512 elderly persons looking for correlation
between anti-HSV-1 IgM positivity (a marker of virus primary
infection or its reactivation) and development of AD-like cog-
nitive dysfunctions (Letenneur et al., 2008). In the same study,
no correlation was found between anti-HSV-1 IgG positivity and
early dementia, thus suggesting that recurrent infection, rather
the primary one, is dangerous for the CNS. Anti-HSV IgM lev-
els, and not those of IgG, have also been found to inversely
correlate with lower plasma Aβ levels (Féart et al., 2011). It is
believed that increased amyloid deposition in the brain is par-
alleled by a lowering of Aβ levels in plasma and that low plasma
Aβ levels might be considered possible short-term risk marker
of dementia (Schupf et al., 2008; Lambert et al., 2009; Blennow
et al., 2010). Another study recently demonstrated that HSV-
1 reactivation, assessed as anti-HSV IgG avidity index (that is
a more accurate way to demonstrate viral reactivation) occurs
in prodromal AD and highly correlates with symptoms of mild
cognitive impairment (Kobayashi et al., 2013). Finally, Mancuso
et al. (2014) recently found that elevated HSV-1 antibody titers
were signiﬁcantly more frequent in AD patients than in control
healthy patients and that they positively correlated with corti-
cal bilateral temporal and orbitofrontal gray matter volume, that
may be considered an index of AD pathology (Whitwell et al.,
2012).
GENETIC DETERMINANTS
Some studies have suggested that in people carrying the APOE-ε4
allele and, therefore, predisposed to develop AD, HSV-1 infection
markedly increases the risk of AD (Itzhaki et al., 1997; Itzhaki and
Lin, 1998; references in Bearer, 2012). However, this correlation
was not always conﬁrmed (Beffert et al., 1998). APOE seems to
affects the outcome of several different infections (Itzhaki et al.,
1998; Dobson et al., 2003) and, interestingly, APOE-ε4 is a risk
factor for cold sores (Itzhaki and Wozniak, 2008). Some studies
also demonstrated that ApoE4 presence inﬂuences the viral load
in the brain. Indeed, viral spreading into the brain of ApoE KO
mice was lower than that occurring in wild-type mice and cor-
relation was reported between ApoE expression and HSV-1 DNA
concentration detected in theCNS (Burgos et al., 2002). In a subse-
quent study, the same authors showed that during acute infection
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with HSV-1, ApoE4 was more efﬁcient than ApoE3 in promoting
viral colonization of the brain (Burgos et al., 2006b). However,
many genes and proteins implicated in AD, other than ApoE, have
been found to interact with herpes simplex viral genome or reg-
ulate its life cycle, further supporting the hypothesized synergy
between host and pathogens in causing AD-like brain damage
(Carter, 2008). From this point of view, genome wide association
investigations (GWAs) carried out in a large cohort of AD and
non-AD subjects also suggested an infective etiology for sporadic
AD. In particular, the polymorphism association of genes located
on the chromosome 19 (i.e., Nectin-2 [NC-2]; APOE, glycopro-
tein carcinoembryonic antigen related cell adhesion molecule-16
[CEACAM-16]; B-cell lymphoma-3 [Bcl-3]; translocase of outer
mitochondrial membrane 40 homolog [TOMM-40]) and on the
chromosome 8 (complement receptor-1 [CR-l]; APOJ, C-type
lectin domain A family-16 member [CLEC-16A]), results in a
genetic ﬁngerprint that might modulate brain susceptibility to
herpes virus infection and lead to neuronal loss, inﬂammation
and Aβ deposition (Porcellini et al., 2010; Licastro et al., 2011).
MOLECULAR DATA
Several studies demonstrated that HSV-1 affects APP process-
ing. HSV-1 infection may have profound effects on the host
intracellular pathways leading to activation/inactivation of sev-
eral signaling molecules and kinases involved in APP metabolism.
Ruth Itzhaki’s group found that in human SH-SY5Y neuroblas-
toma cells HSV-1 induces APP cleavage with the production of
a 55-kDa fragment (recognized in Western blot analysis by an
anti-C-terminal APP antibody) starting from 6 h post infection
(hpi), and the concomitant reduction of band intensity relative to
full-length APP (Shipley et al., 2005). These authors also reported
that HSV-1 infection caused Aβ40 and Aβ42 accumulation in
human neuroblastoma and glioblastoma cells in vitro, whereas
in brains of mice infected with HSV-1 they only found an increase
in Aβ42 (Wozniak et al., 2007). However, further studies on in vivo
models of recurrent HSV-1 brain infections are needed to deter-
mine the structural and functional alterations induced by viral
reactivation.
We have demonstrated that in cultured neuronal cells HSV-1
induces amyloidogenic APP cleavage, with production of sev-
eral APP-Fs including Aβ (De Chiara et al., 2010; Piacentini et al.,
2011). In particular, we found that infection of SH-SY5Y human
neuroblastoma cells and rat cortical neurons with HSV-1 induces
multiple cleavages of APP, which result in the intra- and/or extra-
cellular accumulation of several APP-Fs with neurotoxic potential.
Among them we found: (i) APP-Fs of 35 and 45 kDa (APP-F35
and APP-F45) that comprise portions of Aβ; (ii) N-terminal APP-
Fs that are secreted extracellularly; (iii) intracellular C-terminal
APP-Fs, including AICD; and (iv) Aβ40 and Aβ42 in the form of
monomers and small oligomers (dimers and trimers). Notably,
the fragment APP-F35 seems to be a large Aβ oligomer (probably
a nonamer) that is typical of viral-induced APP processing given
that it was only found in cells infected with HSV-1. Indeed, it
was revealed with antibodies recognizing amino-acidic sequences
in Aβ (e.g., 4G8 and M2◦, targeting amino acids 17–24 and
1–10 of Aβ, respectively), only 8–18 hpi (Figures 1 and 2A).
Moreover, its formation was inhibited in the presence of β- and
γ-secretase inhibitors. APP-F45 was revealed by M2◦ only. On
the contrary, neither of these APP-Fs were recognized by anti-
bodies raised against the N- and C-terminals of APP (Figure 1),
thus indicating that they are not APP cleavage end-products. We
also demonstrated that APP-Fs were present in the extracellular
space and they had the ability to induce apoptosis in the neigh-
boring cells (De Chiara et al., 2010). The multiple cleavages of
APP occurring in infected cells are produced in part by known
components of the amyloidogenic APP processing pathway, i.e.,
host-cell β-secretase, γ-secretase, and caspase-3-like enzymes, and
in part by other cellular or viral enzymes not yet identiﬁed. Inci-
dentally, the increased production of Aβ also reﬂected in an
increased production and nuclear accumulation of AICD frag-
ment that it is known to play a role in AD by modulating gene
transcription.
It has been hypothesized that viral glycoprotein B is responsible
for Aβ aggregation because this glycoprotein shares a signiﬁcant
portion of amino acid sequence similarity with Aβ, and it might
serve as“core”to triggerAβ aggregation (Cribbs et al., 2000). How-
ever, we and others (Wozniak et al., 2007; Piacentini et al., 2011)
found that HSV-1-induced increased Aβ immunoreactivity was
not due to cross-reactivity of the anti-Aβ antibodies with this
glycoprotein.
From a functional point of view, we reported that HSV-1 bind-
ing to neuronal membrane induced membrane depolarization
leading to increased neuronal excitability and triggering action
potentials. This depolarization was due to activation of persis-
tent Na+ currents and inhibition of leak K+ currents. Neuronal
hyperexcitability persisted over time and was observed in neu-
rons also at 12 hpi. Downstream to this effect we observed
increased intracellular Ca2+ signaling, mainly due to activation
of L-type Ca2+ channels and opening of inositol trisphosphate
receptors (InsP3Rs) that caused marked intracellular Ca2+ entry
from extracellular medium and Ca2+ release from intracellular
stores (Piacentini et al., 2011). As above described, this Ca2+ dys-
regulation may trigger neurodegeneration (Mattson and Chan,
2003; Piacentini et al., 2008a,b; Chakroborty et al., 2012). We also
found that HSV-1 induced Ca2+-mediated APP phosphorylation
at Thr668. This is a key event critically involved in APP pro-
cessing and Aβ formation (Pierrot et al., 2006). We demonstrated
that HSV-1 infection induces a signiﬁcant accumulation of Aβ42
inside neurons (Figure 2), and this effect depended on Ca2+ sig-
naling activation. Indeed, in the presence of nifedipine and/or
2-aminoethoxydiphenyl borate (2-APB), that are speciﬁc blockers
of L-type Ca2+ channels and InsP3 receptors, respectively, intra-
neuronal Aβ accumulation was signiﬁcantly reduced (Piacentini
et al., 2011). Besides accumulating inside neurons, Aβ monomers
and small oligomers (dimers and trimers) were also released in the
culture medium of infected neurons and revealed by Western blot
analysis.
Several other studies have investigated the link between HSV-
1 and AD at molecular level, independently on APP processing.
It has been demonstrated that HSV-1 infection causes several
functional and molecular alterations including: neurodegenera-
tion andAD-like phosphorylation of tau protein (Zambrano et al.,
2008; Wozniak et al., 2009b), the latter involving the activation of
the glicogen sinthase kinase 3; caspase-3-mediated cleavage of Tau
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FIGURE 1 | HSV-1 infection induces APP cleavage. (A) Our data suggest
that HSV-1 binding to the heparan sulfate proteoaminoglycans (HSPGs)
expressed on neuronal plasma membrane induces Ca2+ signals triggering
APP phosphorylation at Thr668 that, in turn, increases β- and γ-secretase
activity. As a result, there is an increased production of Aβ that aggregates
to form oligomers of various size. The C-terminal APP fragment called AICD,
created by the cleavage of γ secretase is phosphorylated at Thr668 and
internalized in the nucleus where it may modulate gene transcription. (B)
Western blots showing representative experiments performed with 4G8
antibody and anti pAPPThr668 on intracellular lysates of neuronal cells.
Asterisks in the blots indicate bands that are modiﬁed by 18 h of HSV-1
infection (hours post infection, hpi) with respect to the mock-infected
conditions. Double asterisk in the Western blot for 4G8 indicates the APP
fragment F35, characteristic of HSV-1 infected cells. (C) Cartoon indicating
the amino acid sequences targeted by the different antibodies we used for
Western blot and immunoﬂuorescence experiments: 4G8 recognizes all
APP fragments containing the amino acid sequence 17–24 of Aβ,
independently on its cleavage. Therefore, it reacts with APP “full-length”,
and with all APP fragments that contain Aβ 17–24 sequence; pAPPThr668
antibody reacts with all C-terminus APP fragments containing
phosphorylated Thr668, including APP full-length; anti Aβ42 C-terminus
speciﬁcally reacts with the C-terminal part of Aβ42, and it does not
recognize APP. Western blots in the panel B refer to previously published
data (De Chiara et al., 2010).
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FIGURE 2 | HSV-1 infection induces intracellular accumulation of
several APP fragments. Representative examples of mock and
HSV-1-infected (18 hpi) rat cortical neurons immunostained for Aβ42
C-terminus (green) and HSV-1 (red;A); pAPPThr668/AICDpThr668 (green)
and MAP-2 (red; B). Nuclei are stained in blue with DAPI.White
arrowheads in the panelA (right) indicate intracellular accumulation of Aβ42
in infected (HSV-1-positive) neurons. In the panel B (right), yellow
arrowheads indicate nuclear accumulation of AICDpThr668 in infected
neurons (MAP-2-positive) whereas white arrowheads indicate staining for
putative APP full-length phosphorylated at Thr668. Images in the panelsA
and B refer to previously published data (Piacentini et al., 2011).
(Lerchundi et al., 2011); activation of the arachidonic acid cas-
cade, which is involved in AD-type neuropathological changes
(Hill et al., 2009). With regard to the interaction between herpes
simplex viruses and APP, it has been recently shown that HSV-
1 alters the distribution of cellular APP, and APP and HSV-1
capsid proteins physically interact to allow the migration of new
viral particles inside infected cells by fast anterograde transport
mechanisms (Cheng et al., 2011). This also suggests that HSV-1
affectsAPPdynamic and its intracellular distribution thus possibly
causing alterations in its metabolism and processing.
POSSIBLE HSV-1 RELATED THERAPEUTIC INTERVENTIONS
Experimental evidence reviewed above allows us to hypothesize
that, in the near future, treatments aimed at preventing and/or
delaying AD might include antiviral agents and/or target HSV-1-
activated intracellular pathways. At the present, the main antiviral
agent used for HSV-1 is Acyclovir. Acyclovir, that is the common
name of acycloguanosine, targets infected cells and inhibits viral
replication (Park et al., 1979). Wozniak et al. (2011) demonstrated
that acyclovir reduced Aβ formation and Tau phosphorylation in
vitro. This ﬁnding suggests that the appearance of molecular AD
hallmarks depends on HSV-1 replication. Similarly, we observed
that in rat cortical neurons, UV-inactivation of HSV-1 parti-
cles prevented Aβ42 formation and its intracellular accumulation,
although the virus retained the ability to bind the neuronal mem-
brane and trigger intracellular signaling leading to short-termAPP
phosphorylation (Piacentini et al., 2011). Itzhaki suggested that
treatment with a variant of acyclovir, the valacyclovir, could be
of great interest in treatment of HSV-1-induced neurodegener-
ation (Itzhaki and Wozniak, 2012). Indeed, valacyclovir displays
greater bioavailability than acyclovir (5-fold to 10-fold), it crosses
the blood brain barrier and has no toxicity when used in patients
with multiple sclerosis (Friedman et al., 2005). Interestingly, lysine
supplementation has been suggested to have a role in preventing
the development of AD by reducing HSV-1 replication (Rubey,
2010).
Among the proposed pharmacological treatments for AD, the
use of statins seems to be promising (Barone et al., 2013). It has
been suggested that their beneﬁcial effects may be related to their
ability to modulate the entry of pathogens given that cholesterol
synthesis inhibition blocks the entry, and limits neuronal spread,
of HSV-1 (Hill et al., 2005).
Finally, some studies also suggested the use of GSK-3β
inhibitors as possible candidates for AD treatment (King et al.,
2014). Among them, lithium has been shown to have some beneﬁ-
cial effects onAD symptoms (see references in Forlenza et al., 2012;
Nunes et al., 2013). Lithiumhas also been reported to inhibit HSV-
1 replication both in vitro and in vivo (Ziaie and Kefalides, 1989;
Ziaie et al., 1994; Amsterdam et al., 1996), thus allowing to spec-
ulate that its beneﬁcial effects might also depend on its antiviral
activity.
CONCLUSION
Data reviewed here support the hypothesis that recurrent HSV-1
infection in the brain may have a critical role in AD pathogenesis
by directly activating intracellular pathways leading to typical AD
molecular hallmarks. Studies ongoing in our laboratory on in vivo
models of recurrent mild brain HSV-1 infection will expectedly
further support the causal relationship between HSV-1 reacti-
vation in the CNS and AD-like cognitive decline. Collectively,
data discussed in this manuscript indicate that greater attention
should be paid to infectious and, especially, viral agents among the
environmental factors contributing to AD pathogenesis.
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